Abstract:The MET receptor activation pathway is intrinsically linked to the activity of the transcription factors ETV1 and ERG (ETS family) to promote tumorigenesis in prostate cancer cells. Here we focus on the transcriptional programme leading to this partnership and have identified 5 commonly regulated target genes that may represent a potential signature of prostate cancer progression at advanced stages. Prostate cancer, the most common malignancy in men, has a relatively favourable prognosis. However, when it spreads to the bone, the survival rate drops dramatically. The development of bone metastases leaves patients with aggressive prostate cancer, the leading cause of death in men. Moreover, bone metastases are incurable and very painful. Hepatocyte growth factor receptor (MET) and fusion of genes encoding E26 transformation‐specific (ETS) transcription factors are both involved in the progression of the disease. ETS gene fusions, in particular, have the ability to induce the migratory and invasive properties of prostate cancer cells, whereas MET receptor, through its signalling cascades, is able to activate transcription factor expression. MET signalling and ETS gene fusions are intimately linked to high‐grade prostate cancer. However, the collaboration of these factors in prostate cancer progression has not yet been investigated. Here, we show, using cell models of advanced prostate cancer, that ETS translocation variant 1 (ETV1) and transcriptional regulator ERG (ERG) transcription factors (members of the ETS family) promote tumour properties, and that activation of MET signalling enhances these effects. By using a specific MET tyrosine kinase inhibitor in a humanised hepatocyte growth factor (HGF) mouse model, we also establish that MET activity is required for ETV1/ERG‐mediated tumour growth. Finally, by performing a comparative transcriptomic analysis, we identify target genes that could play a relevant role in these cellular processes. Thus, our results demonstrate for the first time in prostate cancer models a functional interaction between ETS transcription factors (ETV1 and ERG) and MET signalling that confers more aggressive properties and highlight a molecular signature characteristic of this combined action.

RON and C-Met Facilitate Metastasis Through the ERK Signaling Pathway in Prostate Cancer Cells.

Potential Therapeutics Specific to C-Met/ron Receptor Tyrosine Kinases for Molecular Targeting in Cancer Therapy.

Aberrant RON and MET Co-overexpression As Novel Prognostic Biomarkers of Shortened Patient Survival and Therapeutic Targets of Tyrosine Kinase Inhibitors in Pancreatic Cancer.

Pathogenesis Of Ron Receptor Tyrosine Kinase In Cancer Cells: Activation Mechanism, Functional Crosstalk, And Signaling Addiction

Functional interaction between receptor tyrosine kinase MET and ETS transcription factors promotes prostate cancer progression

B-Raf Activation Cooperates with Pten Loss to Drive C-Myc Expression in Advanced Prostate Cancer

Upregulation of COPB2 Promotes Prostate Cancer Proliferation and Invasion Through the MAPK/TGF-β Signaling Pathway

RON in hepatobiliary and pancreatic cancers: Pathogenesis and potential therapeutic targets

A Noncanonical E3 Ubiquitin Ligase RNF41-mediated MYO1C Stability Promotes Prostate Cancer Metastasis by Inducing Actin Remodeling

Identification of cofilin-1 as a novel mediator for the metastatic potentials and chemoresistance of the prostate cancer cells

Ezrin Expression in Circulating Tumor Cells is a Predictor of Prostate Cancer Metastasis

The metastatic promoter DEPDC1B induces epithelial‐mesenchymal transition and promotes prostate cancer cell proliferation via Rac1‐PAK1 signaling

CXCL1-LCN2 paracrine axis promotes progression of prostate cancer via the Src activation and epithelial-mesenchymal transition

MiR-573 Inhibits Prostate Cancer Metastasis by Regulating Epithelial-Mesenchymal Transition.

MiR-1 Inhibits Prostate Cancer PC3 Cells Proliferation Through the Akt/mTOR Signaling Pathway by Binding to C-Met

NRP1 promotes prostate cancer progression via modulating EGFR-dependent AKT pathway activation

Prostate tumor RON receptor signaling mediates macrophage recruitment to drive androgen deprivation therapy resistance through Gas6-mediated Axl and RON signaling

Convergent Rank- And C-Met-Mediated Signaling Components Predict Survival Of Patients With Prostate Cancer: An Interracial Comparative Study

Intrinsic FGFR2 and Ectopic FGFR1 Signaling in the Prostate and Prostate Cancer

Tumor microenvironment promotes prostate cancer cell dissemination via the Akt/mTOR pathway

Curcumin Inhibits Cancer-Associated Fibroblast-Driven Prostate Cancer Invasion Through MAOA/mTOR/HIF-1α Signaling.